| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$11,436,450 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-03 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
41,443 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-03 |
4 |
AS |
$174.20 |
$405,886 |
D/D |
(2,330) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-28 |
4 |
OE |
$131.89 |
$280,266 |
D/D |
2,125 |
41,238 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-08-28 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-10-01 |
4 |
AS |
$194.62 |
$475,846 |
D/D |
(2,445) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-10-01 |
4 |
OE |
$155.57 |
$380,369 |
D/D |
2,445 |
41,558 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-02 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
40,909 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-02 |
4 |
AS |
$175.36 |
$314,947 |
D/D |
(1,796) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-05 |
4 |
AS |
$172.08 |
$400,946 |
D/D |
(2,330) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-05 |
4 |
OE |
$86.52 |
$201,592 |
D/D |
2,330 |
41,443 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-07 |
4 |
OE |
$131.89 |
$280,266 |
D/D |
2,125 |
41,238 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-07 |
4 |
AS |
$181.89 |
$386,516 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2018-11-15 |
4 |
AS |
$163.75 |
$16,375 |
D/D |
(100) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-01-18 |
4 |
OE |
$155.70 |
$190,421 |
D/D |
1,223 |
40,336 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-01-18 |
4 |
AS |
$194.62 |
$238,020 |
D/D |
(1,223) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-01-22 |
4 |
OE |
$131.89 |
$280,266 |
D/D |
2,125 |
41,238 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-01-22 |
4 |
AS |
$193.48 |
$411,145 |
D/D |
(2,125) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-04 |
4 |
AS |
$189.19 |
$780,598 |
D/D |
(4,126) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-04 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
41,443 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
31,020 |
70,133 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-11 |
4 |
AS |
$179.46 |
$5,939,188 |
D/D |
(32,956) |
37,177 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-19 |
4 |
AS |
$186.81 |
$1,051,716 |
D/D |
(5,624) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-05-15 |
4 |
AS |
$165.41 |
$15,052 |
D/D |
(91) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-08-19 |
4 |
AS |
$186.37 |
$2,329,976 |
D/D |
(12,501) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-08-19 |
4 |
OE |
$86.52 |
$1,290,681 |
D/D |
12,501 |
36,212 |
0 |
- |
|
157 Records found
|
|
Page 3 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
